Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 76.83% is 101% above its 5-year average of -5748.04%, near the low end of its 5-year range (-74018.49%–7386600.00%).
104.41% above its 12-month average of -1741.08%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
76.83%
GROSS MARGIN AVG TTM
-1741.08%
GROSS MARGIN AVG 3Y
16.81%
GROSS MARGIN AVG 5Y
-5748.04%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+104.41%
CURRENT VS 3Y AVG
+357.08%
CURRENT VS 5Y AVG
+101.34%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.38%
median of 786 covered companies
CURRENT VS SECTOR MEDIAN
+90.27%
vs the sector median at left
Relay Therapeutics, Inc.
Market Cap
$4.03B
Gross Margin
76.83%
TTM Avg
-1741.08%
3Y Avg
16.81%
5Y Avg
-5748.04%
Market Cap
$4.06B
Gross Margin
61.64%
TTM Avg
80.82%
3Y Avg
86.99%
5Y Avg
87.36%
Market Cap
$4.28B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.67B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.40B
Gross Margin
83.86%
TTM Avg
80.36%
3Y Avg
82.01%
5Y Avg
82.83%
Market Cap
$4.42B
Gross Margin
75.44%
TTM Avg
66.98%
3Y Avg
64.58%
5Y Avg
67.25%
Market Cap
$4.43B
Gross Margin
80.08%
TTM Avg
75.94%
3Y Avg
72.82%
5Y Avg
72.82%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Relay Therapeutics, Inc. (RLAY) | $4.03B | 76.83% | -1741.08% | 16.81% | -5748.04% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.06B | 61.64% | 80.82% | 86.99% | 87.36% |
| ICU Medical, Inc. (ICUI)vs › | $3.96B | 37.56% | 35.69% | 33.68% | 34.73% |
| LivaNova PLC (LIVN)vs › | $4.15B | 68.18% | 68.59% | 68.31% | 67.52% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.28B | 0.00% | 0.00% | 0.00% | 0.00% |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.67B | 0.00% | 0.00% | 0.00% | 0.00% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.40B | 83.86% | 80.36% | 82.01% | 82.83% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.42B | 75.44% | 66.98% | 64.58% | 67.25% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.43B | 80.08% | 75.94% | 72.82% | 72.82% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.54B | 71.45% | 69.72% | 68.83% | 69.16% |
Gross Margin
76.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 83.20% |
| 2025-12-31 | 91.44% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | -8980.06% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | -723.45% |
| 2023-12-31 | 7386600.00% |
| 2023-09-30 | -223.36% |
| 2023-06-30 | -74018.49% |
| 2023-03-31 | -36549.12% |
| 2022-12-31 | -25167.59% |
| 2022-09-30 | -19347.67% |
| 2022-06-30 | -16478.36% |
| 2022-03-31 | -12231.03% |
| 2021-12-31 | -8908.82% |
| 2021-09-30 | -6529.88% |
| 2021-06-30 | -5249.17% |
| 2021-03-31 | -3116.60% |
| 2020-12-31 | 98.90% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
